Search Results

1-20 of 31 results for primarymember:"Patsy Calton"

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

To ask the Secretary of State for Health, what plans he has to increase the number of sign language interpreters for profoundly deaf people attending for NHS treatment.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

17 November 2004

Reference

196280; 426 c1693W;426 c1696W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what assessment has been made of the possibility of urine-based drug therapies providing a route for human-to-human transmission of (a) CJD and (b) other diseases.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

19 April 2004

Reference

420 c229-30W;420 c230-1W; 162496

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what plans he has to publish information on waiting times for treatment of cancers not covered by NHS Cancer Plan targets before 2005; what progress has been made towards meeting the targets for cancer treatment in the NHS Cancer Plan. - Inc...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

5 March 2004

Reference

418 c1157-8W;418 c1173-4W; 157771;157773

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, pursuant to his Answer of 16th December 2003 to the honourable Member for Christchurch, Official Report, 415 c877W, on brachytherapy treatment, by what date the Department will have decided whether the treatment referred to is a suitable topic for referral to the...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

25 February 2004

Reference

418 c463-4W;418 c483-4W; 154938

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, how many haemophiliacs in the United Kingdom have been treated in each year since 1975 for (a) hepatitis C and (b) CJD acquired from contaminated blood products. - Not available centrally.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

5 February 2004

Reference

417 c1063W; 146985

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, pursuant to his Answer of 13th January, Official Report, 416 c708-9W, what assessment he has made of the difference in costs between GM and animal insulins. - Inc figures.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

5 February 2004

Reference

417 c1066W; 152391

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what assessment he has made of the continuing availability of animal insulin; what assessment he has made of the difference in cost to the NHS of prescriptions of animal insulin as compared to GM insulin per 1000 prescriptions; what assessment he has...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

6 January 2004

For answer on

13 January 2004

Answered on

13 January 2004

Mrs. Calton: To ask the Secretary of State for Health (1) what assessment he has made of the continuing availability of animal insulin; [147016] (2) what assessment he has made of the difference in cost to the NHS of prescriptions of animal insulin as compared to GM insulin per 1,000 prescriptions; [147017] (3) what assessment he has made of the benefits of GM insulin as against animal insulin. [147019] Ms Rosie Winterton: There are two companies supplying animal insulin in the United Kingdom. The Department is in regular contact with these companies and both have confirmed that they will continue to supply animal insulin for the foreseeable future. There has been no assessment or forecast made of the difference in cost of prescriptions of animal and genetically modified insulin per 1,000 prescriptions. However, the table shows the number of prescription items that were dispensed in the community in England, and their cost, in the 12 months ended June 2003 and the average net ingredient cost per item. Number of prescription items, net ingredient cost and average net ingredient cost per item of insulins that were dispensed in the community in England for the 12 months ending June 2003 _________________________________________________________________________________________________. Number of prescription items Net ingredient cost (£000) Average net ingredient cost per (£000) item (£) Highly purified animal 128.1 4,217.2 32.92 Human sequence (GM insulin) 3,522.0 150,528.8 42.74 All insulins 3,650.0 154,746.0 42.40 _________________________________________________________________________________________________. Notes: 1. The data are from the Prescription Cost Analysis (PCA) system which covers all prescription items that are dispensed in the community in England. This does not include drugs dispensed in hospitals or private prescriptions. 2. Insulins are those defined in the British National Formulary (BNF) paragraph 6.1.1, "Insulins". Insulin drugs have been grouped into highly purified animal and human sequence (GM) insulin in line with the British National Formulary (BNF) 3. Doctors write prescriptions on a prescription form. Each single item written on the form is counted as a prescription item. The net ingredient cost refers to the cost (which the dispenser is reimbursed) of the drug before discounts and does not include drugs dispensed in hospitals or private prescriptions.

Date

13 January 2004

Reference

416 c708-9W;416 c706-7W; 147016;147017;147019

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what measures the forthcoming National Service Framework for Renal Services module on the effective delivery of dialysis will put in place to increase (a) the availability of and (b) equality of access to dialysis services; when he intends to publish the modules...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

9 December 2003

For answer on

15 December 2003

Answered on

15 December 2003

Mrs. Calton: To ask the Secretary of State for Health (1) what measures the forthcoming National Service Framework for Renal Services module on the effective delivery of dialysis will put in place to increase (a) the availability of and (b) equality of access to dialysis services; [143941] (2) when he intends to publish the modules of the National Service Framework for Renal Services on the effective delivery of dialysis and transplantation; and what the timescale is for the development and publication of the modules on primary prevention and alternative models of care; [143942] (3) how the forthcoming National Service Framework for Renal Services module on transplantation will incorporate the Transplant Framework for England, Saving Lives, Valuing Donors; [143979] (4) what measures will be included in the the forthcoming National Service Framework for Renal Services specifically to increase care in the treatment and management of renal disease among ethnic minorities; [143980] (5) whether he intends to publish an implementation plan alongside the National Service Framework for Renal Services, with specific timelines for implementation. [143981] Ms Rosie Winterton: The national service framework (NSF) for renal services will be published shortly. It will set standards of care for people with renal failure to be achieved over the next 10 years. Details of how the standards can be implemented will be embraced in the document. The NSF will build upon other work, including the "National Service Framework for Diabetes and Saving Lives, Valuing Donors: a Transplant Framework for England". Work on the primary prevention and care towards the end of life modules is in development.

Date

15 December 2003

Reference

415 c778W; 143941;143942;143979;143980;143981

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, how many and what proportion of patients use (a) animal and (b) GM-produced human insulin; what assessment has been made of the (i) likely changes in those figures over the next ten years and (ii) continuing availability of animal insulin; and if...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

17 November 2003

For answer on

20 November 2003

Answered on

20 November 2003

Mrs. Calton: To ask the Secretary of State for Health how many and what proportion of patients use (a) animal and (b) GM-produced human insulin; what assessment has been made of the (i) likely changes in those figures over the next 10 years and (ii) continuing availability of animal insulin; and if he will make a statement. [139904] Ms Rosie Winterton: Data on the number of people using animal and genetically modified produced human insulins are not collected and there has been no assessment or forecast made of the numbers of people likely to be using these insulins in the future. The table shows the number of prescription items that were dispensed in the community in England, and their cost, in the 12 months ended June 2003. Number of prescription items and net ingredient cost of insulins that were dispensed in the community in England for the 12 months ending June 2003 _________________________________________________________________________________________________. Number of prescription items (thousand) Net ingredient cost (£000) Highly purified animal insulin 128.1 4,217.2 Human sequence (GM insulin) 3,522.0 150,528.8 All insulins 3,650.0 154,746.0 _________________________________________________________________________________________________. Notes: 1. The data is from the Prescription Cost Analysis (PCA) system which covers all prescription items that are dispensed in the community in England. This does not include drugs dispensed in hospitals or private prescriptions. 2. Insulins are those defined in the British National Formulary (BNF) paragraph 6.1.1, "Insulins". Insulin drugs have been grouped into highly purified animal and human sequence (GM) insulin in line with the British National Formulary (BNF). 3. Doctors write prescriptions on a prescription form. Each single item written on the form is counted as a prescription item. The net ingredient cost refers to the cost (which the dispenser is reimbursed) of the drug before discounts and does not include any dispensing costs or fees.

Date

20 November 2003

Reference

139904; 413 c1390W;413 c1386W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, if he will amend the Cancer Patient Information Strategy to ensure that information on (a) diagnosis and (b) treatment is available for all people affected by (i) breast cancer and (ii) cancer in general who want it.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

17 November 2003

Reference

137454; 413 c575-6W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, which primary care trusts support a dysphasia service; and which of these have received external funding.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

5 November 2003

Reference

132784; 412 c687W;412 c686W

House

House of Commons

LIVING WILLS

That this House welcomes the growing use of living wills, which allow patients to set out the medical treatments they would accept or refuse should they lose the ability to communicate; recognises that they are also a great help to health professionals because they give them a better understanding of...

Primary sponsor

Patsy Calton (Liberal Democrat)

Type

Early day motions

Date

5 November 2003

Reference

1874

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what plans he has to ensure that (a) specialist care is available for endometriosis and (b) patient counsellors are available in (i) gynaecology wards and (ii) general practices.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

1 September 2003

Reference

124187; 409 c931-2W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what plans he has to provide further funding to enable research into endometriosis to progress. - Inc ref to 1 September 2003, 409 c932W.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

1 September 2003

Reference

124188; 409 c932W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what measures are in place to prevent discrimination in the treatment of older people with breast cancer.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

10 July 2003

Reference

124372; 408 c1001W;408 c999W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what funding was available for research into a cure for myeloma in each of the last five years; and if he will make a statement about future funding. - Including figures and fact that recently management of the research supported by these...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

24 June 2003

For answer on

8 July 2003

Answered on

8 July 2003

Mrs. Calton: To ask the Secretary of State for Health what funding was available for research into a cure for myeloma in each of the last five years; and if he will make a statement about future funding. [122028] Miss Melanie Johnson: The main Government agency for research into the causes of and treatments for disease is the Medical Research Council (MRC) which receives its funding from the Department of Trade and Industry via the Office for Science and Technology. The MRCs expenditure on research on myeloma is shown in the table. _________________________________________________________________________________________________. Year £ 1998-99 410,000 1999-2000 390,000 2000-01 360,000 2001-02 420,000 2002-03 not available _________________________________________________________________________________________________. The MRC has also supported two major myeloma studies: Myeloma VII and Myeloma VIII. Because the MRC has changed the way in which information is kept about funding of trials, the figures in the table do not include spend on these two studies. The MRC has recently awarded £1 million to the Myeloma IX trial involving 1,600 patients. This trial will evaluate a number of different therapies and modalities of treatment used and being developed for myeloma, to provide information on their impact on response rates, survival and quality of life. The MRC funds a considerable amount of basic underpinning research which is excluded from site- specific figures. As a guide, the MRC spent £75 million on cancer research in 2001-02. In addition, research classified as undertaken in one site may well have implications in another--leukaemia would be a relevant example in the case of myeloma. The Department of Health meets the national health service support costs of research funded by the MRC and research charities. In 2000-01, an estimated £73.2 million was spent on cancer research through research and development allocations to NHS organisations. Management of the research supported by these allocations is devolved and expenditure at project level is not held centrally by the Department.

Date

8 July 2003

Reference

122028; 408 c780W;408 c777-8W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what recent assessment he has made of delays in the diagnosis of myeloma. - Inc figures and ref to www.doh.gov.uk/cancerwaits.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

4 July 2003

Reference

122027; 408 c541W;408 c540-1W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what assessment he has made of the availability of hydrotherapy treatment for MS sufferers; and if he will make a statement. - Inc fact that we do not hold information centrally on the availability of these therapies.

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

3 July 2003

Reference

122800; 408 c489W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, how his Department monitors compliance by PCTs with the requirement that funds are made available for the implementation of NICE guidance not later than three months after issue; and if he will make a statement; what further plans he has to address...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

12 June 2003

For answer on

23 June 2003

Answered on

23 June 2003

Mrs. Calton: To ask the Secretary of State for Health (1) how his Department monitors compliance by PCTs with the requirement that funds are made available for the implementation of NICE guidance not later than three months after issue; and if he will make a statement; [119669] (2) what further plans he has to address the local variations in prescribing atypical antipsychotic drugs for the treatment of people with schizophrenia; and if he will make a statement; [119670] (3) what measures are being taken to increase the number of primary care trusts who are implementing the National Institute for Clinical Excellence guidance on HTA; [119674] (4) what estimate he has made of the number of people who do not have access to the most modern drugs to treat schizophrenia as set out in the National Institute for Clinical Excellence guidance of June 2002. [119675] Ms Rosie Winterton: The National Institute for Clinical Excellence (NICE) issued guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia in June 2002. It is recommended that atypical antipsychotics should be considered as options for the treatment of schizophrenia. The clinician responsible for prescribing the medication should do so following appropriate assessment of the patient and taking into account the views of the patient (or their advocate if appropriate), and the relative benefits and side effects. The statistics currently available on the use of atypical antipsychotics indicate a continuing rise in the prescribing of these products, but no estimates are available of the number of patients who may not be receiving treatment in accordance with NICE guidance. National health service bodies are under a statutory obligation to fund treatments recommended in NICE technology appraisals. We expect primary care trusts (PCTs) to meet their statutory obligations, and strategic health authorities to follow up any allegations of non- compliance. We last reminded PCTs of their obligations in guidance published in January 2003.

Date

23 June 2003

Reference

119669;119670;119674;119675; 407 c580W;407 c584W

House

House of Commons

Dept of Health

To ask the Secretary of State for Health, what discussions he has had with ministerial colleagues on after-care support, with particular reference to (a) housing, (b) education and (c) employment for those treated for alcohol dependency; what discussions he has had with the drinks industry on the labelling of alcoholic...

Asked by

Patsy Calton (Liberal Democrat)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

12 June 2003

For answer on

20 June 2003

Answered on

20 June 2003

Mrs. Calton: To ask the Secretary of State for Health (1) what discussions he has had with ministerial colleagues on after-care support, with particular reference to (a) housing, (b) education and (c) employment for those treated for alcohol dependency; [119905] (2) what discussions he has had with the drinks industry on the labelling of alcoholic drinks (a) to indicate alcohol units and (b) with health warnings; [119908] (3) what steps he is taking to ensure that those with alcohol dependency who are receiving treatment (a) receive medical intervention and (b) have the causes of their dependency addressed.; [119944] (4) whether it is his policy that the maximum target waiting time for those with alcohol dependency should be no longer than three weeks from time of referral to receipt for treatment; [119945] (5) what steps he will take to ensure that accessible and suitable treatment services for alcohol dependency are provided to everyone who needs them; [119946] (6) whether it is his policy to designate the tackling of alcohol dependency as having the same priority as addressing drug abuse. [119947] Miss Melanie Johnson: My right hon. Friend, the Prime Minister's Strategy Unit, in close collaboration with other Government Departments, including the Department of Health, is currently developing the national alcohol harm reduction strategy, which will sit alongside the national drugs strategy. The Strategy Unit is due to publish an interim analysis of the harms associated with alcohol misuse in the summer. The final report, which will set out the cross-Governmental alcohol harm reduction strategy, is planned for publication in the autumn. As part of this project the Strategy Unit and the then Under-Secretary of State for Health, my hon. Friend the Member for Salford (Ms Blears), have had on-going discussions with all relevant stakeholders, including the alcoholic drinks industry. There is currently no specific maximum waiting time target for treatment for those with alcohol dependency. However the final report will consider a wide variety of issues around treatment and support for those dependent on alcohol, and will then move to consider specific policy issues, including unit and warning labelling. Provision of appropriate health service provision is the responsibility of local commissioners of services based on assessment of need. There is a wide range of services available for those with alcohol problems requiring treatment. Medical management is available in primary and secondary care. Specialist services provide a range of psychotherapeutic interventions focusing on alcohol use and the wider contributory factors to development of dependence.

Date

20 June 2003

Reference

407 c477-8W;407 c478-9W; 119905;119908;119944;119945;119946;119947

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher